Evotec Overview
- Status
-
Private
- Employees
-
4,500
- Latest Deal Type
-
M&A
- (Cancelled)
- Financing Rounds
-
15
- Investments
-
67
Evotec General Information
Description
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
Contact Information
Website
www.evotec.comCorporate Office
- Essener Bogen 7
- 22419 Hamburg
- Germany
Corporate Office
- Essener Bogen 7
- 22419 Hamburg
- Germany
Evotec Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Evotec Comparisons
Industry
Financing
Details
Evotec Competitors (37)
One of Evotec’s 37 competitors is uniQure, a Formerly VC-backed company based in Amsterdam, Netherlands.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| uniQure | Formerly VC-backed | Amsterdam, Netherlands | ||||
| Novartis | Corporation | Basel, Switzerland | ||||
| Sinovac Biotech | Corporation | Beijing, China | ||||
| Astellas Pharma | Corporation | Tokyo, Japan | ||||
| Selvita | Corporation | Krakow, Poland |
Evotec Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Evotec Patents
Evotec Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20190062423-A1 | Methods for reduction of pathological fibrosis and associated disorders and diseases | Inactive | 04-Sep-2015 | ||
| US-20210403554-A1 | Methods for reduction of pathological fibrosis and associated disorders and diseases | Inactive | 04-Sep-2015 | ||
| WO-2017040916-A2 | Methods for reduction of pathological fibrosis and associated disorders and diseases | Inactive | 04-Sep-2015 | ||
| EP-3344260-A2 | Modulation of gpr124 for reduction of pathological fibrosis | Inactive | 04-Sep-2015 | ||
| WO-2017040916-A3 | Modulation of gpr124 for reduction of pathological fibrosis | Inactive | 04-Sep-2015 | C07K16/28 |
Evotec Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Evotec Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Evotec Investments & Acquisitions (67)
Evotec’s most recent deal was a Later Stage VC with Centauri Therapeutics for . The deal was made on 01-Jul-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Centauri Therapeutics | 01-Jul-2026 | Later Stage VC | Drug Discovery | ||
| Aeovian Pharmaceuticals | 13-May-2024 | Later Stage VC | Drug Discovery | ||
| Tubulis | 14-Mar-2024 | Later Stage VC | Drug Discovery | ||
| NephThera | 01-Jul-2023 | Merger/Acquisition | Drug Discovery | ||
| Cajal Therapeutics | 29-Nov-2022 | Early Stage VC | Drug Discovery |
Evotec Exits (14)
Evotec’s most recent exit was on 14-Mar-2024 from Tubulis. The exit was categorized as with 13 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Tubulis | 14-Mar-2024 | Completed |
|
||
| Tubulis | 03-May-2022 | Completed |
|
||
| Immunitas Therapeutics | 18-Aug-2021 | Completed |
|
||
| Exscientia | 27-Apr-2021 | Completed |
|
||
| OxVax | 21-Apr-2021 | Seed Round | Completed |
|
Evotec Affiliates
Subsidiaries (8)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Evotec Gt | Vienna, Austria | 2019 | |
| Sanofi (Toulouse Operations) | Paris, France | 2014 | |
| Evotec Id (Lyon) | Lyon, France | 2014 | |
| Rigenerand | Medolla, Italy | 2009 | |
| Kuecept | Potters Bar, United Kingdom | 2007 |
Evotec FAQs
-
Where is Evotec headquartered?
Evotec is headquartered in Hamburg, Germany.
-
What is the size of Evotec?
Evotec has 4,500 total employees.
-
What industry is Evotec in?
Evotec’s primary industry is Drug Discovery.
-
Is Evotec a private or public company?
Evotec is a Private company.
-
What is the current valuation of Evotec?
The current valuation of Evotec is .
-
What is Evotec’s current revenue?
The current revenue for Evotec is .
-
How much funding has Evotec raised over time?
Evotec has raised $634M.
-
Who are Evotec’s investors?
Triton Partners, CARB-X, Mubadala Investment Company, BVF Partners, and Novo Holdings are 5 of 9 investors who have invested in Evotec.
-
Who are Evotec’s competitors?
uniQure, Novartis, Sinovac Biotech, Astellas Pharma, and Selvita are some of the 37 competitors of Evotec.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
